The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.00
Bid: 9.00
Ask: 9.50
Change: -0.65 (-6.74%)
Spread: 0.50 (5.556%)
Open: 9.50
High: 10.20
Low: 9.00
Prev. Close: 9.00
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

10 Oct 2022 08:03

RNS Number : 3180C
e-Therapeutics plc
10 October 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B2823H99

Issuer Name

E-THERAPEUTICS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

Other

Comments

This is due to a placing of subscription shares.

3. Details of person subject to the notification obligation

Name

M&G Plc

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

06-Oct-2022

6. Date on which Issuer notified

07-Oct-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

17.500840

0.000000

17.500840

101875000

Position of previous notification (if applicable)

9.813161

0.000000

9.813161

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00B2823H99

101875000

17.500840

Sub Total 8.A

101875000

17.500840%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

M&G Plc

M&G Plc (Parent Company)

17.500840

17.500840%

M&G Plc

M&G Group Regulated Entity Holding Company Limited (wholly owned subsidiary of M&G Plc)

17.500840

17.500840%

M&G Plc

M&G Group Limited (wholly owned subsidiary of M&G Group Regulated Entity Holding Company Limited)

17.500840

17.500840%

M&G Plc

M&G FA Limited (wholly owned subsidiary of M&G Group Limited)

17.500840

17.500840%

M&G Plc

M&G Investment Management Limited (wholly owned subsidiary of M&G FA Limited)

17.500840

17.500840%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

07-Oct-2022

13. Place Of Completion

London, United Kingdom

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAXEEFEAAFEA
Date   Source Headline
27th Jun 20147:00 amRNSChange of Adviser
25th Jun 20144:11 pmRNSDirector/PDMR Shareholding
25th Jun 20143:57 pmRNSHolding(s) in Company
20th Jun 20144:22 pmRNSHolding(s) in Company
20th Jun 20141:41 pmRNSHolding(s) in Company
18th Jun 20146:14 pmRNSAdditional Listing
30th May 20147:00 amRNSAnnual Financial Report and Notice of AGM
22nd May 20144:15 pmRNSIssue of Equity
12th May 20147:00 amRNSFull year results
8th May 20147:00 amBUSe-Therapeutics announces recruitment resumes into US phase I ETS2101 brain cancer trial
2nd May 20144:46 pmRNSHolding(s) in Company
2nd May 20144:42 pmRNSHolding(s) in Company
2nd May 20144:29 pmRNSHolding(s) in Company
25th Apr 20147:00 amRNSNotice of Results
7th Apr 20141:07 pmRNSDirectorate Change
7th Apr 201411:46 amRNSDirectorate Change
31st Mar 20146:56 amBUSe-Therapeutics reports positive interim results from UK phase Ia trial of ETS2101 (dexanabinol) in a variety of solid tumours
26th Mar 20147:00 amBUSe-Therapeutics announces recruitment resumes into UK phase I ETS2101 cancer trial
10th Feb 20147:02 amBUSe-Therapeutics Begins Phase I Study of Oral Formulation of Anti-Cancer Compound ETS2101 with Healthy Volunteers
24th Jan 20147:00 amBUSTemporary halt of recruitment into ETS2101 cancer trials because of drug supply issue - Patients already being treated will continue to be dosed
9th Jan 20142:34 pmRNSAdditional Listing
7th Jan 20147:00 amBUSStatement re e-Therapeutics provides update on ETS2101 phase I trial in brain cancer
31st Oct 20137:00 amBUSResearch Update
16th Oct 20137:00 amBUSHalf-yearly Report
30th Sep 20134:45 pmRNSDirector/PDMR Shareholding
19th Sep 20137:00 amRNSNotice of Interim Results
6th Aug 201312:43 pmRNSAdditional Listing
1st Aug 20134:53 pmRNSDirector/PDMR Shareholding
30th Jul 20133:30 pmRNSDirector/PDMR Shareholding
25th Jul 201311:09 amRNSResult of AGM
24th Jul 201312:53 pmRNSDirector/PDMR Shareholding
3rd Jul 20134:41 pmRNSDirector/PDMR Shareholding
1st Jul 20139:00 amRNSNotice of AGM and Annual Report
21st Jun 20137:00 amRNSProactive Investors One2One Forum 26th Manchester
18th Jun 20134:11 pmRNSManchester One2One Investors Forum - June 26
14th May 20137:00 amBUSPreliminary results for the year ended 31 January 2013
18th Apr 20137:00 amRNSNotice of Results
4th Apr 20135:18 pmRNSDirector/PDMR Shareholding
25th Mar 201310:44 amRNSHolding(s) in Company
18th Mar 20135:19 pmRNSIssue of Equity
13th Mar 20136:19 pmRNSHolding(s) in Company
6th Mar 201310:01 amRNSHolding(s) in Company
5th Mar 20135:44 pmRNSHolding(s) in Company
4th Mar 20133:31 pmRNSHolding(s) in Company
4th Mar 20133:23 pmRNSDirector/PDMR Shareholding
4th Mar 20132:56 pmRNSHolding(s) in Company
1st Mar 20137:00 amRNSCompletion of the Placings
28th Feb 201312:01 pmRNSCompletion of First Placing / Issue of Equity
27th Feb 201310:01 amRNSResult of General Meeting / Issue of Equity
22nd Feb 20132:51 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.